Feb. 15, 2006 – Nanosphere Inc., a nanotechnology-based molecular diagnostics company, and Applied NeuroSolutions Inc. (OTCBB:APNS), a company focused on the development of an integrated product portfolio for the diagnosis and treatment of Alzheimer’s disease, announced this week a research collaboration for the development of diagnostic tests for Alzheimer’s disease. Both companies are based in Illinois.
This research program will apply Nanosphere’s proprietary Biobarcode(TM) technology for protein detection to Applied NeuroSolutions’ proprietary biomarkers, which have been shown to be 85 to 95 percent accurate in the detection of Alzheimer’s disease. Ultra-sensitive detection of these markers has the potential to lead to the next generation of diagnostic tests for Alzheimer’s disease.